Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study

Renata Abrahão, MD, MSc, PhD; Sandra Perdomo, PhD; Luis Felipe Ribeiro Pinto, PhD; Flávia Nascimento de Carvalho, MSc; Fernando Luís Dias, MD, PhD; José Roberto V. de Podestá, MD; Sandra Ventorin von Zeidler, PhD; Priscila Marinho de Abreu, PharmD, MSc; Marta Vilensky, BS; Raul Eduardo Giglio, MD; José Carlos Oliveira, PhD; Matinair Siqueira Mineiro, RN; Luiz P. Kowalski, MD, PhD; Mauro K. Ikeda, PhD; Mauricio Cuello, MD; Andres Munyo, MD; Paula A. Rodríguez-Urrego, MD; José Antonio Hakim, MD; David Alfonso Suarez-Zamora, MD; Federico Cayol, MD; Marcelo Fernando Figari, MD; Javier Oliver, PhD; Valerie Gaborieau, DUT; Ruth H. Keogh, DPhil; Paul Brennan, PhD; and Maria Paula Curado, PhD, MD on behalf of the InterCHANGE Group

PURPOSE Head and neck squamous cell carcinoma (HNSCC) incidence is high in South America, where recent data on survival are sparse. We investigated the main predictors of HNSCC survival in Brazil, Argentina, Uruguay, and Colombia.

METHODS Sociodemographic and lifestyle information was obtained from standardized interviews, and clinicopathologic data were extracted from medical records and pathologic reports. The Kaplan-Meier method and Cox regression were used for statistical analyses.

RESULTS Of 1,463 patients, 378 had a larynx cancer (LC), 78 hypopharynx cancer (HC), and 599 oral cavity cancer (OC), and 408 oropharynx cancer (OPC). Most patients (55.5%) were diagnosed with stage IV disease, ranging from 47.6% for LC to 70.8% for OPC. Three-year survival rates were 56.0% for LC, 54.7% for OC, 48.0% for OPC, and 37.8% for HC. In multivariable models, patients with stage IV disease had approximately 7.6 (LC/HC), 11.7 (OC), and 3.5 (OPC) times higher mortality than patients with stage I disease. Current and former drinkers with LC or HC had approximately 2 times higher mortality than never-drinkers. In addition, older age at diagnosis was independently associated with worse survival for all sites. In a subset analysis of 198 patients with OPC with available human papillomavirus (HPV) type 16 data, those with HPV-unrelated OPC had a significantly worse 3-year survival compared with those with HPV-related OPC (44.6% vs 75.6%, respectively), corresponding to a 3.4 times higher mortality.

CONCLUSION Late stage at diagnosis was the strongest predictor of lower HNSCC survival. Early cancer detection and reduction of harmful alcohol use are fundamental to decrease the high burden of HNSCC in South America.
PATIENTS AND METHODS

Patients

We used data prospectively collected from the INTER-CHANGE study, a multicenter case-control study that was initiated to investigate the risk factors for HNSCC onset and outcomes. Patients were followed up to investigate the main predictors of survival after HNSCC. The International Agency for Research on Cancer (IARC; Lyon, France) was responsible for the overall coordination of the study, which included 8 institutions from the following 4 countries: Argentina, Brazil, Colombia, and Uruguay. Data from Argentina were mostly from the Angel Roffo Institute of Oncology (Buenos Aires; public health system), with a few patients from the Italiano Hospital (Buenos Aires; private). Data from Brazil are from the following 4 centers: National Cancer Institute (INCA) in Rio de Janeiro (public), Araujo Jorge Hospital in Goiania (private), A.C. Camargo Cancer Center in Sao Paulo (private), and Santa Rita de Cassia Hospital in Vitoria (private). Uruguay was represented by the Dr Manuel Quintela Hospital in Montevideo (public), whereas data from Colombia were obtained from the Santa Fe de Bogota University Hospital (Bogota; private).

Inclusion criteria included age ≥ 18 years and a diagnosis of a primary HNSCC from 2011 to 2017. HNSCC was classified according to the International Classification of Diseases for Oncology, third edition, and included LC (C32.0-C32.9), HC (C12.9 and 13C.0-13C.9), OC (C00.3-C00.9, C02.0-C02.3, C03.0-C03.9, C04.0-C04.9, C05.0, and C06.0-C06.9), and OPC (C01.0-C01.9, C02.4, C05.1-C05.2, C09.0-C09.9, and C10.0-10.9). All tumors were confirmed by histology.

Explanatory Variables

All patients participated in a standardized interview conducted within 6 months of diagnosis, during which information on sociodemographic, lifestyle, and clinical factors was collected. Sociodemographic variables included residence at time of recruitment, sex (male or female), age at diagnosis (≤ 50, 51-60, 61-70, or ≥ 71 years), education level (categorized as illiterate, fundamental incomplete, fundamental complete, medium complete, or superior), and self-identified race or ethnicity (white, black, mulatto, or other/unknown). Mulattos are considered to be people of mixed African and European descent. As a result of small numbers, Asians, indigenous, and mestizo (mixed indigenous and European descent people from Colombia) patients were grouped in the race or ethnicity category of other.

Lifestyle variables included comprehensive tobacco and alcohol histories. Tobacco use included cigarettes, cigars, and pipes, and the following 3 aspects were investigated: overall smoking history (never-smoker, former smoker, or current smoker), (2) smoking duration (categorized as never, 1-39, or ≥ 40 years), and (3) smoking intensity (categorized as never, < 30, or ≥ 30 pack-years). Alcohol intensity was examined as overall alcohol history (never-drinker, former drinker, or current drinker) and alcohol intensity (categorized as ≤ 2 or > 2 drinks per day). Alcohol use included all types of alcohol, such as cachaça, vodka, whisky, tequila, rum, gin, beer, and wine.

Clinicopathologic data were obtained from medical records and pathologic reports. Stage at diagnosis was based on the seventh edition of the TNM classification of the American Joint Committee on Cancer (AJCC) and classified into four categories (stage I-IV). Institutions from Buenos Aires, Goiania, and Victoria provided additional information on HPV-16 E6 serology (a highly specific biomarker of HPV-16 infection) for patients with OPC, which corresponded to nearly 50% of patients with OPC. Patients with high seroreactivity (mean fluorescent intensity, ≥ 1,000) were considered to have HPV-related OPC.

Follow-Up

The primary outcome was overall survival, which was measured from the date of HNSCC diagnosis until death from any cause, the end of the study (June 31, 2018), or loss to follow-up, whichever occurred first. Patients contribute person-years of follow-up from their date of diagnosis to the date of death, loss to follow-up, or end of study. Therefore, there was a maximum of 7.5 years of
follow-up (January 1, 2011, to June 31, 2018). Information on vital status was obtained via routine follow-up visits and/or by linking the patient’s data with vital statistics, cancer registry files, and medical records, depending on the available sources at each center. IARC provided an online database to enter follow-up information. For the main analysis, we assumed that a patient was lost to follow-up when he or she could not be tracked by any source of information in the last 24 months of the study completion.

**Statistical Analyses**

Analyses were performed separately by anatomic cancer site. Because of the relatively small sample size, patients with HC were pooled with patients with LC for multivariable regression analysis. We estimated the probability of 3-year survival using the Kaplan-Meier method and compared differences in survival curves across strata for each variable using the log-rank test.

To evaluate the association between survival and the explanatory variables, we used hazard ratios (HRs) and 95% CIs estimated by means of Cox proportional hazards models. Variables included in the models were those that had an a priori hypothesized or previously observed association with HNSCC survival based on a review of the literature. These include age and stage at diagnosis, sex, education, race or ethnicity, and smoking and alcohol histories. Univariable and multivariable models (including all variables) were fitted. All multivariable models were adjusted for calendar year of diagnosis (categorized as 2011-2013 and 2014-2017) and center to account for possible changes in therapeutic management over time and different treatment approaches, respectively. The model with combined LC and HC was additionally adjusted for tumor site as a result of the potential differences in prognosis between the 2 types of cancer. The model for OPC also included HPV status because differences in prognosis between HPV-related and HPV-unrelated OPC have been reported.

The proportional hazards assumption, assessed by examining log-log survival plots and Schoenfeld residuals, was met for all variables in the multivariable models. Likelihood ratio tests were used to obtain overall P values for each variable in the multivariable models, considering comparison with the model excluding the variable in question. A small amount of data was missing for some explanatory variables, and all analyses were restricted to patients with complete data on all variables used in the multivariable models, thus assuming that the data were missing completely at random. All statistical analyses were performed using Stata 14.2 statistical software (StataCorp, College Station, TX). A 2-sided P < .05 was considered statistically significant.

**Ethics Approval**

The InterCHANGE study was approved by the ethical review boards of the IARC and of each participating center. All patients provided written informed consent for their participation in this study.

**RESULTS**

From 2011 through 2017, a total of 1,829 patients newly diagnosed with HNSCC were enrolled in the InterCHANGE study. Patients with missing (n = 18), overlapping (n = 101), or “other” (n = 65) topography codes and those with missing (n = 100) or inconsistent date of known last vital status (at or before date of diagnosis, n = 7) were excluded from the study. Less than 5% of patients (n = 75) had missing data for ≥1 of the explanatory variables and were excluded. The proportions of individuals with missing data were 3.1% for stage, 1.5% for education, 0.4% for smoking history, and 0.5% for alcohol history. The proportion of patients lost to follow-up was 17.4%.

Analyses were based on 1,463 patients with a complete set of information. Of these patients, 378 (25.8%) had LC, 78 (5.3%) had HC, 599 (40.9%) had OC, and 408 (27.9%) had OPC. Most patients were from Brazil (n = 1,174, 80.3%), followed by Argentina (n = 228, 15.6%), Uruguay (n = 32, 2.2%), and Colombia (n = 29, 2.0%). Approximately 55.5% of patients were diagnosed with stage IV tumors, varying from 47.6% for LC to 70.8% for OPC. The baseline characteristics of the participants are listed in Table 1.

By the end of the follow-up period, 672 patients (45.9%) had died, and the median follow-up time was 1.7 year (range, 0.1-6.9 years). On the basis of Kaplan-Meier analyses, 3-year survival was estimated to be highest for LC (56.0%; 95% CI, 50.3% to 61.2%) and OC (54.7%; 95% CI, 50.3% to 58.9%), intermediate for OPC (48.0%; 95% CI, 42.4% to 53.3%), and lowest for HC (37.8%; 95% CI, 25.9% to 49.6%). On the basis of the log-rank test, worse survival was associated with advanced stage at diagnosis (Fig 1), lower education (OC and OPC), smoking (OC and OPC), alcohol consumption (LC and OPC), male sex (OPC), and older age at diagnosis (OPC; Appendix Table A1).

For LC and HC combined, univariable analyses showed that advanced stage at diagnosis and alcohol consumption were associated with higher mortality rates. The mortality hazard in patients with HC was 1.7 times that in patients with LC (Table 2). In multivariable-adjusted models, the hazard for mortality was higher among older patients (≥71 v ≤50 years: HR, 1.73; 95% CI, 0.99 to 3.02), mulattos (v whites: HR, 1.44; 95% CI, 1.02 to 2.02), those with advanced stage (IV v I: HR, 7.62; 95% CI, 3.49 to 16.64), and ever-drinkers (current v never: HR, 2.27; 95% CI, 1.36 to 3.77; and former v never: HR, 2.06; 95% CI, 1.24 to 3.41). After multivariable adjustment, the mortality hazard in patients with HC was approximately 1.6 times that in patients with LC (HR, 1.57; 95% CI, 1.08 to 2.30; Table 2).

For patients with OC, univariable analyses revealed that advanced stage at diagnosis, lower education level, and smoking history were associated with higher mortality rates.
| Characteristic                     | All HNSCC | Larynx | Hypopharynx | Oral Cavity | Oropharynx | P* |
|-----------------------------------|-----------|--------|-------------|-------------|------------|----|
| Total                             | 1,463     | 378    | 78          | 599         | 408        |    |
| Countries                         |           |        |             |             |            | < .0001 |
| Argentina                         | 228       | 84     | 7           | 68          | 69         |    |
| Brazil                            | 1,174     | 279    | 63          | 517         | 315        |    |
| Colombia                          | 29        | 6      | 2           | 6           | 15         |    |
| Uruguay                           | 32        | 9      | 6           | 8           | 9          |    |
| Period of diagnosis               |           |        |             |             |            | .2180 |
| 2011-2013                         | 989       | 266    | 52          | 411         | 260        |    |
| 2014-2017                         | 474       | 112    | 26          | 188         | 148        |    |
| Age at diagnosis, years           |           |        |             |             |            | < .0001 |
| ≤ 50                              | 247       | 35     | 19          | 110         | 83         |    |
| 51-60                             | 508       | 135    | 26          | 188         | 159        |    |
| 61-70                             | 437       | 134    | 18          | 167         | 118        |    |
| ≥ 71                              | 271       | 74     | 15          | 134         | 48         |    |
| Median age, years (range)         | 60 (21-95)| 62 (32-94)| 59 (39-83) | 61 (22-95) | 58 (21-85)|    |
| Sex                               |           |        |             |             |            | .0001 |
| Male                              | 1,185     | 329    | 70          | 441         | 345        |    |
| Female                            | 278       | 49     | 8           | 158         | 63         |    |
| Race/ethnicity                    |           |        |             |             |            | .1360 |
| White                             | 900       | 247    | 41          | 366         | 246        |    |
| Black                             | 134       | 26     | 9           | 57          | 42         |    |
| Mulatto                           | 384       | 98     | 23          | 161         | 102        |    |
| Other/unknown                     | 45        | 7      | 5           | 15          | 18         |    |
| Stage at diagnosis                |           |        |             |             |            | < .0001 |
| I                                 | 174       | 58     | 3           | 95          | 18         |    |
| II                                | 190       | 46     | 9           | 102         | 33         |    |
| III                               | 287       | 94     | 14          | 111         | 68         |    |
| IV                                | 812       | 180    | 52          | 291         | 289        |    |
| Education level                   |           |        |             |             |            | .0430 |
| Superior                          | 106       | 24     | 3           | 39          | 40         |    |
| Medium complete                   | 182       | 43     | 10          | 91          | 38         |    |
| Fundamental complete              | 252       | 62     | 14          | 104         | 72         |    |

(Continued on following page)
| Characteristic       | All HNSCC | Larynx | Hypopharynx | Oral Cavity | Oropharynx |
|----------------------|-----------|--------|-------------|-------------|------------|
|                      | No. of Patients | %      | No. of Patients | %      | No. of Patients | %      |
| Fundamental incomplete | 777      | 53.1  | 220          | 58.2        | 41         | 52.6       | 295  | 49.2       | 221  | 54.2 |
| Illiterate           | 146      | 10.0  | 29           | 7.7         | 10         | 12.8       | 70   | 11.7       | 37   | 9.1  |
| Smoking history      |           |       |              |             |            |            |
| Never-smoker         | 221      | 14.4  | 33           | 8.7         | 11         | 14.1       | 121  | 20.2       | 46   | 11.3 |
| Former smoker        | 496      | 33.9  | 153          | 40.5        | 20         | 25.6       | 175  | 29.2       | 148  | 36.3 |
| Current smoker       | 756      | 51.7  | 192          | 50.8        | 47         | 60.3       | 303  | 50.6       | 214  | 52.4 |
| Alcohol history      |           |       |              |             |            |            |
| Never-drinker        | 251      | 17.1  | 69           | 18.3        | 5          | 6.4        | 131  | 21.9       | 46   | 11.3 |
| Former drinker       | 567      | 38.8  | 145          | 38.4        | 38         | 48.7       | 211  | 35.2       | 173  | 42.4 |
| Current drinker      | 645      | 44.1  | 164          | 43.4        | 35         | 44.9       | 257  | 42.9       | 189  | 46.3 |

NOTE. Values are numbers and percentages, unless otherwise indicated.
Abbreviation: HNSCC, head and neck squamous cell carcinoma.

*χ² P value.
In multivariable-adjusted models, mortality hazards were significantly higher among patients age ≥ 61 years (61-70 v ≤ 50 years: HR, 1.46; 95% CI, 0.99 to 2.14; and ≥ 71 v ≤ 50 years: HR, 1.82; 95% CI, 1.18 to 2.78) and those with advanced-stage disease (IV v I: HR, 11.7; 95% CI, 6.09 to 22.43; Table 3).

Among patients with OPC, univariable analyses showed that older age, male sex, lower education, advanced stage at diagnosis, ever-smoker status, and ever-drinker status were associated with higher mortality rates (Table 4). After adjustment, mortality rates remained higher among men (v women: HR, 1.84; 95% CI, 1.08 to 3.14), patients age ≥ 61 years (61-70 v ≤ 50 years: HR, 2.17; 95% CI, 1.36 to 3.46; and ≥ 71 v ≤ 50 years: HR, 2.97; 95% CI, 1.68 to 5.24), and patients with advanced-stage disease (IV v I: HR, 3.49; 95% CI, 1.53 to 7.99; Table 4). In a subset analysis of 198 patients with OPC with available HPV-16 status (48.5% of all patients with OPC), 3-year survival was lower among patients with HPV-unrelated versus HPV-related OPC (44.6% v 75.6%, respectively; Fig 2). Patients with HPV-unrelated OPC had a mortality rate 3.4 times that of patients with HPV-related OPC after multivariable adjustment (HR, 3.35; 95% CI, 1.33 to 8.45; Table 4).

Similar associations between mortality and smoking duration and intensity and alcohol intensity were observed when compared with overall histories for all cancer sites (Appendix Table A2). When we performed an analysis restricted to centers with > 100 patients (INCA in Rio de Janeiro, A.C. Camargo Cancer Center in São Paulo, Santa Rita de Cassia in Vitória, Araújo Jorge in Goiania, and Angel Roffo in Buenos Aires; total of 1,400 patients), 3-year survival did not differ substantially from results across centers.

**DISCUSSION**

The InterCHANGE study provided relevant information on the predictors of survival after larynx, hypopharynx, oral cavity, and oropharynx squamous cell carcinoma using up-to-date information (2011-2017) from 8 centers in 4 countries in South America. Three-year overall survival was < 50% for HC and OPC and slightly > 50% for LC and OC. Late stage at diagnosis was a strong independent predictor of worse survival for all HNSCC sites. Other predictors of lower survival were older age at diagnosis for all anatomic sites.
sites, alcohol consumption (former or current drinkers) for LC/HC, male sex and low education level for OPC, and mulatto race/ethnicity for LC/HC. In addition, in a subset analysis, HPV-unrelated OPC was associated with significantly inferior survival compared with HPV-related OPC.

The proportion of stage IV HNSCCs was strikingly high (56%) in our cohort. If we combine stages III and IV, approximately 75% of patients were diagnosed at later stages. HNSCC diagnosis includes clinical and pathologic information. Although immunohistochemical HPV testing has prognostic significance, this test is not currently mandatory to make therapeutic decisions for patients with OPC not included in deintensification trials. Reasons for late HNSCC diagnosis in South America are often multifactorial and may include:

### Table 2. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Larynx and Hypopharynx Cancers Combined

| Factor                        | No. of Patients | Univariable HR (95% CI) | P* | Multivariable HR (95% CI) | P* |
|-------------------------------|-----------------|-------------------------|----|--------------------------|----|
| **Age at diagnosis, years**   |                 |                         |    |                          |    |
| ≤ 50                          | 54              | Reference               | .2960 | Reference               | .0270 |
| 51–60                         | 161             | 0.89 (0.56 to 1.42)     | .87 (0.53 to 1.43) |
| 61–70                         | 152             | 1.17 (0.74 to 1.85)     | 1.29 (0.79 to 2.12) |
| ≥ 71                          | 89              | 1.22 (0.74 to 2.01)     | 1.73 (0.99 to 3.02) |
| **Sex**                       |                 |                         |    |                          |    |
| Male                          | 399             | 1.38 (0.88 to 2.17)     | .1467 | 1.07 (0.65 to 1.75)     | .7888 |
| Female                        | 57              | Reference               |     | Reference               |     |
| **Race/ethnicity**            |                 |                         |    |                          |    |
| White                         | 288             | Reference               | .0223 | Reference               | .0111 |
| Black                         | 35              | 1.37 (0.85 to 2.19)     | 1.42 (0.84 to 2.41) |
| Mulatto                       | 121             | 1.23 (0.91 to 1.67)     | 1.44 (1.02 to 2.02) |
| Other/unknown                 | 12              | 0.17 (0.02 to 1.23)     | 0.13 (0.02 to 0.99) |
| **Stage at diagnosis**        |                 |                         |    |                          |    |
| I                             | 61              | Reference               | < .0001 | Reference               | < .0001 |
| II                            | 55              | 3.49 (1.46 to 8.35)     | 3.53 (1.45 to 8.59) |
| III                           | 108             | 4.59 (2.08 to 10.17)    | 4.60 (2.05 to 10.32) |
| IV                            | 232             | 7.63 (3.56 to 16.32)    | 7.62 (3.49 to 16.64) |
| **Education level**           |                 |                         |    |                          |    |
| Superior                      | 27              | Reference               | .1325 | Reference               | .7191 |
| Medium complete               | 53              | 1.17 (0.51 to 2.69)     | 0.99 (0.42 to 2.33) |
| Fundamental complete          | 76              | 1.33 (0.61 to 2.89)     | 0.87 (0.39 to 1.95) |
| Fundamental incomplete        | 261             | 1.80 (0.88 to 3.68)     | 1.11 (0.53 to 2.32) |
| Illiterate                    | 39              | 1.44 (0.63 to 3.32)     | 0.82 (0.32 to 2.14) |
| **Smoking history**           |                 |                         |    |                          |    |
| Never-smoker                  | 44              | Reference               | .0939 | Reference               | .3129 |
| Former smoker                 | 173             | 1.66 (0.94 to 2.93)     | 1.72 (0.94 to 3.18) |
| Current smoker                | 239             | 1.77 (1.02 to 3.10)     | 1.66 (0.91 to 3.01) |
| **Alcohol history**           |                 |                         |    |                          |    |
| Never-drinker                 | 74              | Reference               | .0007 | Reference               | .0029 |
| Former drinker                | 183             | 2.04 (1.28 to 3.27)     | 2.06 (1.24 to 3.41) |
| Current drinker               | 199             | 2.27 (1.43 to 3.61)     | 2.27 (1.36 to 3.77) |
| **Tumor site**                |                 |                         |    |                          |    |
| Larynx                        | 378             | Reference               | .0028 | Reference               | .0219 |
| Hypopharynx                   | 78              | 1.71 (1.23 to 2.39)     | 1.57 (1.08 to 2.30) |

Abbreviation: HR, hazard ratio.
*Likelihood ratio test.
Adjusted for all variables in the table plus center and calendar year of diagnosis.
lack of awareness of cancer signs and symptoms (in both patients and health care providers), lack of access to appropriate health care, and shortage of medical resources as a result of fragmented health systems.\textsuperscript{12-14} Nearly half of the participants in our study (n = 677, 46.3\%) were treated at public hospitals, where patients frequently face a significant delay in cancer diagnosis.\textsuperscript{15} Whenever a delay in diagnosis occurs, the potential curability of HNSCC decreases considerably.\textsuperscript{12,16} Importantly, we found that stage at diagnosis was strongly associated with worse survival for all HNSCC sites, regardless of the center of treatment. Although not directly comparable, results from the United States and Europe also show a high proportion of advanced-stage disease (regional or distant) at diagnosis. For instance, data from the American Cancer Society showed that, during 2007-2013, 66\% of patients with OC and OPC were diagnosed with advanced disease.\textsuperscript{17} In Europe, a study that investigated survival after HNSCC from 86 cancer registries during 1999-2007 revealed that 54\% of patients were diagnosed at an advanced stage (regional or metastatic).\textsuperscript{6} These results highlight the unmet need of

### TABLE 3. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Oral Cavity Cancer

| Factor                  | Oral Cavity (n = 599) | Univariable HR (95\% CI) | P*  | Multivariable HR\textsuperscript{a} (95\% CI) | P*  |
|-------------------------|-----------------------|--------------------------|-----|---------------------------------------------|-----|
| Age at diagnosis, years |                       |                          |     |                                             |     |
| ≤ 50                    | 110                   | Reference                | .5702 | Reference                                   | .0114 |
| 51-60                   | 188                   | 1.05 (0.73 to 1.51)      | 1.03 (0.71 to 1.50) |
| 61-70                   | 167                   | 1.17 (0.81 to 1.68)      | 1.46 (0.99 to 2.14) |
| ≥ 71                    | 134                   | 1.28 (0.87 to 1.88)      | 1.82 (1.18 to 2.78) |
| Sex                     |                       |                          | .3293 |                                             | .6497 |
| Male                    | 441                   | 1.15 (0.86 to 1.53)      | 1.09 (0.75 to 1.57) |
| Female                  | 158                   | Reference                | Reference |
| Race/ethnicity          |                       |                          | .1659 |                                             | .1048 |
| White                   | 366                   | Reference                | Reference |
| Black                   | 57                    | 1.05 (0.69 to 1.57)      | 0.90 (0.58 to 1.39) |
| Mulatto                 | 161                   | 1.20 (0.92 to 1.58)      | 1.10 (0.82 to 1.47) |
| Other/unknown           | 15                    | 0.36 (0.09 to 1.46)      | 0.25 (0.06 to 1.06) |
| Stage at diagnosis      |                       |                          | < .0001 |                                             | < .0001 |
| I                       | 95                    | Reference                | Reference |
| II                      | 102                   | 2.31 (1.11 to 4.82)      | 2.41 (1.15 to 5.04) |
| III                     | 111                   | 4.59 (2.32 to 9.09)      | 4.97 (2.49 to 9.90) |
| IV                      | 291                   | 9.27 (4.90 to 17.56)     | 11.7 (6.09 to 22.43) |
| Education level         |                       |                          | .0205 |                                             | .2103 |
| Superior                | 39                    | Reference                | Reference |
| Medium complete         | 91                    | 1.49 (0.74 to 3.01)      | 0.88 (0.42 to 1.83) |
| Fundamental complete    | 104                   | 1.97 (1.00 to 3.90)      | 1.16 (0.56 to 2.39) |
| Fundamental incomplete  | 295                   | 1.81 (0.95 to 3.44)      | 1.01 (0.50 to 2.01) |
| Illiterate              | 70                    | 2.72 (1.36 to 5.46)      | 1.56 (0.73 to 3.36) |
| Smoking history         |                       |                          | .0478 |                                             | .1864 |
| Never-smoker            | 121                   | Reference                | Reference |
| Former smoker           | 175                   | 0.83 (0.57 to 1.21)      | 0.63 (0.38 to 1.05) |
| Current smoker          | 303                   | 1.18 (0.85 to 1.64)      | 0.73 (0.44 to 1.23) |
| Alcohol history         |                       |                          | .1918 |                                             | .3217 |
| Never-drinker           | 131                   | Reference                | Reference |
| Former drinker          | 211                   | 1.03 (0.73 to 1.46)      | 0.96 (0.59 to 1.55) |
| Current drinker         | 257                   | 1.27 (0.92 to 1.77)      | 1.19 (0.74 to 1.92) |

Abbreviation: HR, hazard ratio.

\textsuperscript{a}Likelihood ratio test.

\textsuperscript{b}Adjusted for all variables in the table plus center and calendar year of diagnosis.
early HNSCC diagnosis, not only in South America but also in several high-income countries.

We observed that older age at diagnosis was independently associated with lower survival for all cancer sites, consistent with previous studies in Europe\(^5\) and North America.\(^18\) Relevant factors that influence HNSCC prognosis among elderly patients are the presence and severity of comorbidities and therapeutic approaches. Relevant comorbidities include cardiovascular and respiratory diseases, which are strongly associated with smoking and alcohol consumption.\(^19\) These comorbidities likely contribute to treatment decisions.\(^20,21\) Although older patients with

### TABLE 4. Relation of Sociodemographic and Clinical Factors to the Hazard of Death for Oropharynx Cancer

| Factor                        | Oropharynx (n = 408) | No. of Patients | Univariable HR (95% CI) | P* | Multivariable HR\(^a\) (95% CI) | P* |
|-------------------------------|----------------------|----------------|-------------------------|----|------------------------------|----|
| Age at diagnosis, years      |                      |                |                         |    |                              |    |
| ≤ 50                          | 83                   | Reference      | .0009                   |    | Reference                    | .0008 |
| 51-60                         | 159                  | 1.74 (1.14 to 2.66) | 1.69 (1.09 to 2.61) |    |                              |    |
| 61-70                         | 118                  | 2.04 (1.31 to 3.17) | 2.17 (1.36 to 3.46) |    |                              |    |
| ≥ 71                          | 48                   | 2.58 (1.56 to 4.28) | 2.97 (1.68 to 5.24) |    |                              |    |
| Sex                           |                      |                |                         |    |                              |    |
| Male                          | 345                  | 1.98 (1.24 to 3.14) | 1.84 (1.08 to 3.14) |    |                              |    |
| Female                        | 63                   | Reference      | Reference               |    |                              |    |
| Race/ethnicity               |                      |                |                         |    |                              |    |
| White                         | 246                  | Reference      | Reference               |    |                              |    |
| Black                         | 42                   | 1.05 (0.68 to 1.63) | 0.97 (0.60 to 1.58) |    |                              |    |
| Mulatto                       | 102                  | 1.01 (0.73 to 1.40) | 1.02 (0.71 to 1.47) |    |                              |    |
| Other/unknown                 | 18                   | 1.18 (0.55 to 2.54) | 1.00 (0.33 to 2.96) |    |                              |    |
| Stage at diagnosis            |                      |                |                         |    |                              |    |
| I                             | 18                   | Reference      | Reference               |    |                              |    |
| II                            | 33                   | 0.97 (0.36 to 2.62) | 1.21 (0.44 to 3.32) |    |                              |    |
| III                           | 68                   | 1.31 (0.54 to 3.18) | 1.86 (0.75 to 4.64) |    |                              |    |
| IV                            | 289                  | 2.43 (1.08 to 5.50) | 3.49 (1.53 to 7.99) |    |                              |    |
| Education level               |                      |                |                         |    |                              |    |
| Superior                      | 40                   | Reference      | Reference               |    |                              |    |
| Medium complete               | 38                   | 0.65 (0.28 to 1.52) | 0.79 (0.32 to 1.94) |    |                              |    |
| Fundamental complete          | 72                   | 1.88 (1.00 to 3.55) | 1.96 (0.96 to 3.99) |    |                              |    |
| Fundamental incomplete        | 221                  | 2.30 (1.30 to 4.09) | 1.99 (1.02 to 3.88) |    |                              |    |
| Illiterate                    | 37                   | 2.09 (1.05 to 4.16) | 1.83 (0.81 to 4.13) |    |                              |    |
| Smoking history               |                      |                |                         |    |                              |    |
| Never-smoker                  | 46                   | Reference      | Reference               |    |                              |    |
| Former smoker                 | 148                  | 2.07 (1.12 to 3.81) | 1.32 (0.67 to 2.59) |    |                              |    |
| Current smoker                | 214                  | 2.67 (1.47 to 4.85) | 1.87 (0.92 to 3.79) |    |                              |    |
| Alcohol history               |                      |                |                         |    |                              |    |
| Never-drinker                 | 46                   | Reference      | Reference               |    |                              |    |
| Former drinker                | 173                  | 3.34 (1.79 to 6.24) | 1.41 (0.65 to 3.02) |    |                              |    |
| Current drinker               | 189                  | 2.84 (1.52 to 5.33) | 1.24 (0.58 to 2.67) |    |                              |    |
| HPV16 status; subset analysis of 198 patients\(^c\) | | | | | | |
| Positive                      | 33                   | Reference      | Reference               |    |                              |    |
| Negative                      | 165                  | 3.32 (1.53 to 7.21) | 3.35 (1.33 to 8.45) |    |                              |    |

Abbreviations: HPV, human papillomavirus; HR, hazard ratio.

\(^a\)Likelihood ratio test.

\(^b\)Adjusted for all variables in the table plus center and calendar year of diagnosis.

\(^c\)HPV16 E6 serology data from Vitoria, Goiania, and Buenos Aires (Angel Roffo).
HNSCC may have limited capacity to endure multimodality treatment (surgery, chemotherapy, and/or radiotherapy), a US study showed that elderly patients with advanced disease who received multimodality treatment had better survival than older patients who received single-modality therapy. A careful assessment of risk and potential benefit of different treatment approaches is crucial to decrease HNSCC mortality and morbidity among elderly patients.

We observed higher mortality rates among ever-smokers with OPC in the univariable analysis, but this association was attenuated after adjustment for covariates. For patients with OPC in the univariable analysis, but this association was attenuated after adjustment for covariates. Higher mortality rates were observed among patients with HPV-related OPC in the univariable analysis, but this association was attenuated after adjustment for covariates.

Our study supports the role of HPV as a prognostic factor for OPC, with patients with HPV-related OPC experiencing better survival than patients with HPV-unrelated cancer, consistent with preceding studies in Europe and North and South America. Given the significant epidemiology changes in OPC observed over the past few decades, studies looking at the potential benefit of primary prevention (HPV vaccination) and secondary prevention (screening for oral HPV infection) are warranted.

This study was limited because we lacked data on patient comorbidities, as well as detailed information on treatment approaches by stage at diagnosis. Because data were collected on patients diagnosed before 2018, we did not use the AJCC 8th edition staging system, which was fully implemented in January 2018. Consequently, we could not evaluate changes in staging classification, particularly for OPC. In addition, at the time of this study, tissue biomarkers for OPC (such as p16 expression) were not available, and this will be the subject of a future research project. However, several studies have demonstrated that HPV-16 E6 antibody is a highly specific biomarker for HPV positivity with false-positive rates < 1%. Data were missing for some explanatory variables. A complete-records analysis was used, which assumes that data are missing completely at random. Deviations from this assumption could result in bias in the estimated associations. However, < 5% of individuals were excluded as a result of missing covariate data; therefore, it is unlikely that this had a significant impact on the results. The extent to which our cohort is representative of patients with HNSCC in South America is unclear, and additional studies including more South American centers are warranted to confirm our findings.

The InterCHANGE project has major strengths. This study represents a multicollaborative research effort to provide actual information on a disease with great mortality and morbidity. We obtained recent (2011-2017), good-quality, prospective data from several hospitals specializing in cancer treatment in South America, providing relevant findings to the literature, where data are scarce. Our study followed a standardized protocol, with all cancers confirmed by histology. We had nearly complete information on stage at diagnosis, which is a strong predictor of HNSCC outcome and is often missing in epidemiologic studies. We collected detailed information on tobacco and alcohol use, which are modifiable risk factors that not only cause HNSCC but also have been associated with cancer prognosis. In addition, we provided information on patients’ race or ethnicity and education level, allowing us to account for social determinants of health, elements that may greatly influence early diagnosis and cancer survival.

In summary, 3-year survival after HNSCC diagnosis was low in the South American centers we studied, especially for OPC and HC. Elderly patients had higher mortality rates, which highlights the need of careful assessment of risk and potential benefit of therapeutic management. Our findings of worse survival among former and current drinkers diagnosed with LC or HC emphasize the need for health policies aimed at decreasing alcohol consumption in the population. This is especially relevant in light of a recent...
a systematic analysis of 195 countries that showed that the total attributable burden of alcohol use was greater than demonstrated in previous studies. Moreover, cancer, including HNSCC, accounted for a substantial proportion of total alcohol-attributable deaths. Finally, late stage at diagnosis was the strongest predictor of HNSCC survival. Efforts to detect cancer at an earlier stage are fundamental to improve survival after HNSCC in South America.

AFFILIATIONS
1Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
2Division of Hematology/Oncology and Center for Healthcare Policy Research, University of California, Davis, Sacramento, CA
3Institute of Nutrition, Genetics, and Metabolism Research, Faculty of Medicine, Universidad El Bosque, Bogotá, Colombia
4University Hospital Foundation Santa Fe de Bogotá, Bogotá, Colombia
5National Cancer Institute, Rio de Janeiro, Brazil
6Santa Rita de Cassia Hospital (AFECC), Vitória, Brazil
7Biotechnology Postgraduate Program, Federal University of Espírito Santo, Vitória, Brazil
8Angel Roffo Institute of Oncology, Buenos Aires, Argentina
9Araújo Jorge Hospital, Goiania, Brazil
10A.C. Camargo Cancer Center, São Paulo, Brazil
11Hospital de Clínicas, Montevideo, Uruguay
12Italiano Hospital, Buenos Aires, Argentina
13Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom

Where authors are identified as personnel of the International Agency for Research on Cancer or WHO, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer or WHO.

CORRESPONDING AUTHOR
Paul Brennan, PhD, International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon, France 69372 Cedex 08; e-mail: BrennanP@iarc.fr.

PRIOR PRESENTATION
Presented at the 6th Annual Symposium on Global Cancer Research, New York, NY, March 15, 2018.

SUPPORT
Supported by the International Agency for Research on Cancer and the European Union’s Horizon 2020 research and innovation program HEADSpAcE under Grant Agreement No. 825771; and R.A. was supported in part by the National Research Service Award (NRSA) for Primary Medical Care (Award No. T32HP300370401).

AUTHOR CONTRIBUTIONS
Conception and design: Sandra Perdomo, Fernando Luis Dias, Luiz P. Kowalski, Mauricio Cuello, José Antonio Hakim, Paul Brennan, Maria Paula Curado

Provision of study materials or patients: Luis Felipe Ribeiro Pinto, Flávia Nascimento de Carvalho, José Roberto V. de Podestá, Sandra Ventorin von Zeitler, Priscila Marinho de Abreu, Marta Vilensky, Raul Eduardo Giglio, José Carlos Oliveira, Matimair Siqueira Mineiro, Luiz P. Kowalski, Mauro K. Ikeda, Mauricio Cuello, Andres Munyo, Paula A. Rodriguez-Urrego, David Alfonso Suarez-Zamora, Federico Cayol, Marcelo Fernando Figari, Javier Oliver, Valerie Gaborieau, Paul Brennan, Maria Paula Curado

ACKNOWLEDGMENT
We thank Hélène Renard and Priscilia Chopard for support in recruitment logistics within InterCHANGE.

REFERENCES
1. Perdomo S, Martin Roa G, Brennan P, et al: Head and neck cancer burden and preventive measures in Central and South America. Cancer Epidemiol Biomarkers Prev 44:S43-S52, 2016 (suppl 1)
2. Lewis A, Kang R, Levine A, et al: The new face of head and neck cancer: The HPV epidemic. Oncology (Williston Park) 29:e16-626, 2015
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
4. Anantharaman D, Abedi-Ardekani B, Beachler DC, et al: Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. Int J Cancer 140:1968-1975, 2017
5. Abrahão R, Anantharaman D, Gaboriau V, et al: The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in Europe: The ARCADE study. Int J Cancer 143:32-44, 2018
6. Gatta G, Botti L, Sánchez MJ, et al: Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCare-5 population-based study. Eur J Cancer 51:2130-2143, 2015
7. Pulte D, Brenner H: Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist 15:994-1001, 2010
8. Fritz A, Percy C, Jack A, et al: International Classification of Diseases for Oncology (ed 3). Geneva, Switzerland, World Health Organization, 2013
9. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
10. Lang Kuhs KA, Anantharaman D, Waterboer T, et al: Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis. Cancer Epidemiol Biomarkers Prev 24:683-689, 2015
11. Amin M, Edge S, Greene F, et al: AJCC Cancer Staging Manual (ed 8). New York, NY, Springer, 2017
12. Strasser-Weippl K, Chavari-Guerra Y, Villarreal-Garza C, et al: Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol 16:1405-1438, 2015
13. Carvalho AL, Pinto J, Schlecht NF, et al: Predictive factors for diagnosis of advanced-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128:313-318, 2002
14. Frenk J, Gómez-Dantés O: Health systems in Latin America: The search for universal health coverage. Arch Med Res 49:79-83, 2018
15. Felippu AW, Freire EC, Silva Rde A, et al: Impact of delay in the diagnosis and treatment of head and neck cancer. Braz J Otorhinolaryngol 82:140-143, 2016
16. Kowalski LP, Carvalho AL: Influence of time delay and clinical upstaging in the prognosis of head and neck cancer. Oral Oncol 37:94-98, 2001
17. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68:7-30, 2018
18. Moye VA, Chandramouleswaran S, Zhao N, et al: Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy. Oncologist 20:159-165, 2015
19. Paleri V, Wight RG, Silver CE, et al: Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice. Oral Oncol 46:712-719, 2010
20. Sanabria A, Carvalho AL, Vartanian JG, et al: Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449-1457, 2007
21. Sanabria A, Carvalho AL, Vartanian JG, et al: Factors that influence treatment decision in older patients with resectable head and neck cancer. Laryngoscope 117:835-840, 2007
22. Álvarez AD, Munño-Esteafan A, Borche G, et al: Cáncer de cabeza y cuello en Uruguay: Análisis de sobrevida en dos centros de referencia. Rev Med Urug 34:21-28, 2018
23. Mayne ST, Cartmel B, Kirsh V, et al: Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 18:3368-3374, 2009
24. Kawakita D, Oze I, Hosono S, et al: Prognostic value of drinking status and aldehyde dehydrogenase 2 polymorphism in patients with head and neck squamous cell carcinoma. J Epidemiol 26:292-299, 2016
25. Leoncini E, Vukovic V, Cadoni G, et al: Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study. Cancer Epidemiol 39:367-374, 2015
26. Pan American Health Organization, WHO: Health in Americas, 2017 Edition: Regional Look and Country Profiles. Washington, DC, Pan American Health Organization, 2017
27. D’Souza G, Anantharaman D, Gheit T, et al: Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents. Oral Oncol 62:20-27, 2016
28. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
29. Gillison ML, Chaturvedi AK, Anderson WF, et al: Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33:3235-3242, 2015
30. Anantharaman D, Gheit T, Waterboer T, et al: Human papillomavirus infections and upper aero-digestive tract cancers: The ARCADE study. J Natl Cancer Inst 105:536-545, 2013
31. Kreimer AR, Johansson M, Waterboer T, et al: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31:2708-2715, 2013
32. Ribeiro KB, Levi JE, Pawlita M, et al: Low human papillomavirus prevalence in head and neck cancer: Results from two large case-control studies in high-incidence regions. Int J Epidemiol 40:489-502, 2011
33. McDaniel JT, Nuhu K, Ruiz J, et al: Social determinants of cancer incidence and mortality around the world: An ecological study. Glob Health Promot 26:41-49, 2019
34. GBD 2016 Alcohol Collaborators: Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1015-1035, 2018
# APPENDIX

| TABLE A1. Three-Year OS After Head and Neck Squamous Cell Carcinoma by Anatomic Site in the InterCHANGE Study (2011-2017) |
|---------------------------------------------------------------|
| **Factor** | **Larynx (n = 378)** | **Hypopharynx (n = 78)** | **Oral Cavity (n = 599)** | **Oropharynx (n = 408)** |
| --- | --- | --- | --- | --- |
| **Overall** | 56.0 (50.3 to 61.2) | 37.8 (25.9 to 46.9) | 54.7 (50.3 to 58.9) | 48.0 (42.4 to 53.3) |
| **Period of diagnosis** |  |  |  |  |
| 2011-2013 | 54.5 (48.0 to 60.6) | 34.7 (21.0 to 48.8) | 55.4 (50.1 to 60.3) | 44.6 (38.0 to 51.0) |
| 2014-2017 | 61.0 (49.5 to 70.7) | 43.7 (21.5 to 64.1) | 53.6 (45.4 to 61.2) | 56.4 (46.5 to 65.1) |
| **Age at diagnosis, years** |  |  |  |  |
| ≤ 50 | 65.2 (45.7 to 79.1) | 43.0 (19.8 to 64.4) | 57.0 (46.4 to 66.2) | 61.3 (48.6 to 71.7) |
| 51-60 | 60.1 (50.5 to 68.4) | 39.5 (18.8 to 59.6) | 55.8 (48.0 to 63.0) | 48.5 (39.7 to 56.8) |
| 61-70 | 52.9 (43.3 to 61.7) | 25.6 (8.0 to 48.0) | 53.0 (44.6 to 60.7) | 41.7 (31.2 to 51.9) |
| ≥ 71 | 49.1 (36.2 to 60.8) | 45.4 (17.8 to 69.7) | 53.6 (43.9 to 62.4) | 36.7 (21.9 to 51.5) |
| **Sex** |  |  |  |  |
| Male | 54.5 (48.4 to 60.1) | 39.0 (26.4 to 51.4) | 53.7 (48.5 to 58.5) | 44.7 (38.7 to 50.5) |
| Female | 65.8 (49.6 to 78.0) | 30.0 (4.4 to 62.8) | 57.8 (49.1 to 65.5) | 67.1 (52.6 to 78.1) |
| **Race/ethnicity** |  |  |  |  |
| White | 57.6 (50.5 to 64.0) | 47.0 (29.1 to 63.0) | 56.5 (50.8 to 61.7) | 48.5 (41.3 to 55.3) |
| Black | 42.4 (22.8 to 60.8) | 29.6 (5.2 to 60.7) | 53.2 (38.6 to 65.8) | 47.1 (30.3 to 62.3) |
| Mulatto | 53.3 (42.3 to 63.1) | 17.3 (4.5 to 36.9) | 49.6 (41.1 to 57.5) | 48.1 (37.3 to 58.1) |
| Other/unknown | 100.0 | 80.0 (20.4 to 96.9) | 81.5 (43.5 to 95.1) | 41.3 (12.7 to 68.5) |
| **Education level** |  |  |  |  |
| Superior | 61.4 (35.3 to 79.5) | 70.5 (52.0 to 82.9) | 62.8 (43.2 to 77.3) |  |
| Medium complete | 77.7 (59.8 to 88.4) | 23.3 (3.6 to 52.9) | 61.9 (50.5 to 71.4) | 76.4 (58.2 to 87.5) |
| Fund complete | 56.5 (41.5 to 69.0) | 60.6 (29.2 to 81.6) | 51.4 (40.5 to 61.2) | 52.6 (39.6 to 64.0) |
| Fundamental incomplete | 52.1 (44.9 to 58.8) | 31.0 (16.4 to 46.9) | 55.2 (48.9 to 61.1) | 37.8 (30.3 to 45.2) |
| Illiterate | 53.3 (33.3 to 69.7) | 43.8 (11.9 to 72.6) | 37.9 (25.4 to 50.5) | 50.2 (32.5 to 65.6) |
| **Stage at diagnosis** |  |  |  |  |
| I | 90.4 (78.5 to 95.9) | 91.6 (83.1 to 95.9) | 71.1 (39.6 to 88.2) |  |
| II | 65.9 (48.2 to 78.8) | 45.7 (11.0 to 75.7) | 76.1 (65.6 to 83.8) | 76.5 (56.6 to 88.1) |
| III | 59.7 (48.3 to 69.4) | 33.3 (10.9 to 58.0) | 58.6 (48.2 to 67.5) | 62.9 (48.9 to 74.1) |
| IV | 40.4 (32.6 to 48.1) | 36.8 (22.8 to 51.0) | 33.8 (27.9 to 39.7) | 39.3 (32.9 to 45.7) |
| **Smoking status** |  |  |  |  |
| Never | 69.7 (49.5 to 83.1) | 54.9 (18.7 to 80.6) | 58.4 (48.4 to 67.1) | 73.4 (55.6 to 85.0) |
| Former | 54.1 (45.1 to 62.3) | 31.4 (12.4 to 52.6) | 61.3 (53.0 to 68.6) | 50.8 (41.7 to 59.1) |
| Current | 55.0 (47.0 to 62.2) | 37.7 (22.4 to 52.9) | 49.8 (43.7 to 55.7) | 41.0 (33.4 to 48.4) |
| **Drinking status** |  |  |  |  |
| Never | 75.5 (62.5 to 84.6) | 40.0 (5.2 to 75.3) | 60.9 (51.3 to 69.2) | 75.4 (58.9 to 86.0) |
| Former | 53.4 (44.2 to 61.7) | 40.5 (24.1 to 56.3) | 59.6 (52.2 to 66.3) | 39.1 (30.8 to 47.2) |
| Current | 49.4 (40.8 to 57.5) | 32.6 (15.0 to 51.5) | 48.0 (41.3 to 54.4) | 49.4 (41.1 to 57.1) |
| **HPV16 status; subset analysis of 198 patients** |  |  |  |  |
| Positive | NA | NA | 75.6 (55.4 to 87.6) |  |
| Negative | NA | NA | 44.6 (35.8 to 53.0) |  |

**Abbreviations:** HPV, human papillomavirus; HR, hazard ratios; NA, not applicable; OS, overall survival.

*Log-rank test *P* value.

Less than 3 years of follow-up.

*HPV16 E6 serology data from Vitoria, Goiania, and Buenos Aires (Angel Roffo).
TABLE A2. Association of Smoking and Alcohol Duration and Intensity to Mortality in the InterCHANGE Study (2011-2017)

| Factor               | Larynx and Hypopharynx | Oral Cavity | Oropharynx |
|----------------------|-------------------------|-------------|------------|
|                      | Multivariable HR a (95% CI) | P b       | Multivariable HR a (95% CI) | P b       | Multivariable HR a (95% CI) | P b       |
| Tobacco duration     |                         |            |            |            |                         |            |            |
| Never                | Reference               | .3343      | Reference  | .2006      | Reference               | .0720      |
| < 30 years           | 1.66 (0.84 to 3.29)     | 0.61 (0.36 to 1.06) | 1.20 (0.59 to 2.46) |
| ≥ 30 years           | 1.38 (0.77 to 2.46)     | 0.68 (0.40 to 1.15) | 1.77 (0.89 to 3.53) |
| Tobacco pack-years   |                         |            |            |            |                         |            |            |
| Never or < 1         | Reference               | .5347      | Reference  | .0649      | Reference               | .3959      |
| 1-39                 | 1.37 (0.77 to 2.45)     | 0.61 (0.39 to 0.96) | 1.35 (0.74 to 2.48) |
| ≥ 40                 | 1.33 (0.76 to 2.33)     | 0.57 (0.36 to 0.92) | 1.50 (0.81 to 2.78) |
| Alcohol intensity    |                         |            |            |            |                         |            |            |
| Never                | Reference               | .0013      | Reference  | .9803      | Reference               | .7383      |
| ≤ 2 drinks per day   | 2.01 (1.15 to 3.51)     | 0.95 (0.57 to 1.58) | 1.26 (0.58 to 2.75) |
| > 2 drinks per day   | 2.31 (1.42 to 3.76)     | 0.95 (0.58 to 1.56) | 1.36 (0.61 to 3.00) |

Abbreviation: HR, hazard ratio.

*Each covariate was assessed in separate models adjusted for sex, age, stage at diagnosis, race/ethnicity, education, center, calendar year of diagnosis, and alcohol and/or smoking histories (never, former, or current), as appropriate.

bLikelihood ratio test.